NCT06896188
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06896188
Title 9-ING-41 Combined with Retifanlimab, Plus Modified FOLFIRINOX for Patients with Advanced Pancreatic Adenocarcinoma (RiLEY) (RiLEY)
Acronym RiLEY
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Anwaar Saeed
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.